Home » Articles » Volume 13 / Year 2024 / Issue 1 » Table Contents » 2024/1 GaBI Journal Table of Contents

2024/1 GaBI Journal Table of Contents

Published on 15 April 2024

Editor’s Letter

First 2024 GaBI Journal issue highlights

Original Research

Budget impact analysis of a rituximab intravenous biosimilar in patients with follicular lymphoma and large B-cell non-Hodgkin lymphoma in Chile

Pharmacokinetic bioequivalence studies of a new Etoricoxib tablet formulation developed using proprietary MiST technology — risk assessment and mitigation using GastroPlus software

Perspective

Comparative efficacy studies of biosimilars: data versus theoretical risks, beliefs, and comfort

Current understanding, knowledge, and perception of biosimilars in a changing landscape of regulatory requirements

Opinion

Preserve the US interchangeable standard that has helped drive physician and patient confidence in biosimilars

---